The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen. A significant improvement of renal function (XrenalPR (renal partial response)) was observed in 77% of patients treated with bortezomib, in 55% with thalidomide and in 43% with lenalidomide (P ¼ 0.011). In multivariate analysis, bortezomib-based therapy was independently associated with a higher probability of renal response compared with thalidomide-or lenalidomide-based therapy. Other important variables included eGFR (estimated glomerular filtration rate) X30 ml/min, age p65 years and myeloma response. Patients treated with bortezomib achieved at least renalPR in a median of 1.34 months vs 2.7 months for thalidomide and 46 months for lenalidomide-treated patients (P ¼ 0.028). In multivariate analysis bortezomib-based therapy, higher doses of dexamethasone (X160 mg during the first month of treatment), an eGFR X30 ml/min and age p65 years were independently associated with shorter time to renal response. In conclusion, bortezomib-based therapies may be more appropriate for the initial management of patients with myeloma-related renal failure; however, thalidomide and lenalidomide are also associated with significant probability of improvement of their renal function.
INTRODUCTION
Renal impairment (RI) is a common complication of multiple myeloma affecting at diagnosis approximately one-fifth of the patients. [1] [2] [3] The presence of RI places the patients at higher risk for complications after antimyeloma treatment and is associated with an increased risk of early death. 4 Myeloma-related RI is a medical emergency and every effort should be made to provide optimal supportive care, hydration, correction of contributing factors and to administer effective and rapidly acting antimyeloma therapy. 5 The treatment of myeloma has changed significantly over the past decade since three novel agents thalidomide, bortezomib and lenalidomide have become standard treatments for relapsed and/or refractory disease and are being increasingly used in the frontline setting. The role of these novel agents in myeloma patients with RI has been previously reported [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and more experience has been accumulated with bortezomib. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] However, a head to head comparison of these agents in patients with RI is lacking. In order to address this issue we analyzed 133 patients with newly diagnosed multiple myeloma, who presented with RI, and were treated in our Department with a novel agent-based regimen over the past decade.
MATERIAL AND METHODS
Between April 2001 and December 2011, 133 patients with newly diagnosed multiple myeloma and RI were treated upfront with a novel agent containing regimen. RI was defined as an estimated glomerular filtration rate (eGFR) p60 ml/min/1.73 m . Based on the definition of moderate renal dysfunction as an eGFRo60 ml/min/ 1.73 m 2 by National Kidney Foundation Kidney Disease Outcomes Quality Initiative, 27 we used this cutoff to define at least moderate renal dysfunction in patients with newly diagnosed myeloma.
Patients were divided into three groups according to the type of novel agent-based treatment. Group T included 62 patients who received a thalidomide-based regimen such as thalidomide with dexamethasone (TD); cyclophosphamide, thalidomide and dexamethasone (CTD); thalidomide with vincristine, doxorubicin, and dexamethasone (T-VAD); or melphalan, prednisone and thalidomide (MPT). Group B included 43 patients who received a bortezomib-based regimen such as bortezomib and dexamethasone (VD); bortezomib, thalidomide and dexamethasone (VTD); or bortezomib, cyclophosphamide and dexamethasone (VCD). Group L consisted of 28 patients who received a lenalidomide-based regimen such as lenalidomide and low-dose dexamethasone (Rd), or melphalan, prednisone and lenalidomide (MPR). Lenalidomide was given at doses that were adjusted to renal function according to current recommendations. 11, 28 Besides antimyeloma treatment, in all patients additional measures were taken that included intravenous hydration, alkalization of urine, correction of hypercalcemia, discontinuation of all nephrotoxic agents and administration of antibiotic prophylaxis. Renal dialysis was offered when indicated.
The degree of restoration of renal function was evaluated according to recently proposed criteria. 5, 29 Renal complete response (renalCR) was defined as a sustained (that is, lasting for at least 2 months) increase of baseline eGFR to 460 ml/min. Renal partial response (renalPR) was defined as an increase of eGFR from o15 to 30-59 ml/min and renal minor response (renalMR) as sustained improvement of baseline eGFR of o15 ml/min to 15-29 ml/min or, if baseline eGFR was 15-29 ml/min, improvement to 30-59 ml/min. According to both EBMT 30 and IMWG 31 response criteria, a partial response required a reduction of the serum M-protein X50% and a concomitant decrease of urine M-protein by X90%. Assessment of response was based on the IMWG criteria, which were also retrospectively applied to patients treated and followed before the publication of the above criteria.
Differences among various groups were compared with the w 2 -test for categorical variables (using Fisher's exact test when appropriate) and with the Mann-Whitney test or ANOVA for continuous variables. Logistic regression analysis was used for multivariate analysis by entering all significant variables (Po0.05), which were associated with renal response. Time to renal response was calculated from the date of initiation of treatment until the date when criteria for renal response were first met. Patients who died before renal response could be evaluated, were censored at the time of their death. Survival was evaluated from the date of treatment initiation until the date of death or last follow-up, and was plotted with the Kaplan-Maier method.
RESULTS

Patients
The characteristics of the patients are shown in Table 1 . Patients in groups T and L were older than those in group B (Po0.001), whereas anemia (hemoglobin o10 g/dl) was more frequent in group L (P ¼ 0.035). Baseline renal function was more severely impaired in patients treated with bortezomib (P ¼ 0.037). Measurement of free light chains (FLCs, Freelite assay) was available in 102 patients (41 in group T, 36 in group B and 25 in group L) ( Table 1) . Among these patients, 64 (63%) patients had involved FLC (iFLC) X500 mg/l and there was a strong correlation between iFLC X500 mg/l and an eGFR o30 ml/min (Po0.001).
Patients in group B and T received significantly higher doses of dexamethasone compared with patients in group L, especially during the first month of therapy. Overall, 68 (51%) of patients had severe RI defined as eGFR o30 ml/min including 10 (7.5%) patients who required dialysis (Table 1 ).
Novel agent-based therapies and renal response An improvement of renal function (that is, at least renalMR) was observed in 81% of patients in group B, in 74% of patients in group T and in 61% of patients in group L (P ¼ 0.153) (Figure 1) . We focused our analysis in major renal responses (that is, renalPR and renalCR), as this degree of improvement of renal function is of more clinical relevance. Thus, renalCR þ renalPR were observed in 77% in group B, in 55% in group T and in 43% in group L (P ¼ 0.011), whereas a complete renal response was achieved in 67% of patients in group B, 53% in group T and 36% in group L (P ¼ 0.032; Table 2 ). Among 10 patients who required dialysis, 5 patients (2 in group T and 3 in group B) became dialysis independent. Among 9 patients who received a combination of bortezomib with thalidomide and dexamethasone (VTD), 6 (67%) achieved a renal response (XrenalMR), 5 (56%) a major renal response (renalCR or renalPR) and 4 (44%) achieved a renalCR. Furthermore, one of two patients who required dialysis became independent of this procedure.
Myeloma response and renal response A myeloma response was achieved in 81% of patients in group B, in 82% of those in group L and in 63% of those in group T (P ¼ 0.05). A myeloma response was associated with a significantly higher probability of at least renalPR (P ¼ 0.002). There was no significant difference in the rates and quality of renal response among patients with different quality of myeloma response (complete response (CR) vs very good partial response (VGPR) vs partial response (PR)): RenalCR rates for patients who achieved CR, VGPR or PR were 60% vs 62% vs 66%, respectively. The rates of any renal response (renalMR or better) for patients with myeloma CR, VGPR or PR were 80%, 89% and 77% respectively, whereas for patients with myeloma stable disease (SD) or progressive disease (PD) were 51% (P ¼ 0.001 for CR, VGPR, PR vs SD/PD); some patients who did not achieve a myeloma PR improved their renal function to at least renalPR (7/22 (22%) in group T, 4/8 (50%) in group B and 1/5 (20%) in group L).
In all patients who achieved a renal response, urine M-protein was reduced by 490% from baseline; median urine M-protein reduction was 98% (range 90-100%). In 10 patients who achieved a major renal response but did not fulfill the other criteria for myeloma response (for example, serum M-peak was reduced by o50%), urine M-protein and/or iFLCs were reduced by 490%. For patients with available measurements for FLCs, median reduction of involved FLC was 88% at first renal response and 90% at best renal response. This reduction was not different for patients who achieved a renal CR/PR vs those who achieved a renalMR (reduction by 89% vs 85% at first renal response and 91% vs 85% reduction at best eGFR, respectively).
Prognostic factors for major renal response Factors that were associated with a higher probability of at least renalPR included eGFR X30 ml/min (HR: 2.3, 95% CI 1.024-4.123, P ¼ 0.043) and age p65 years (HR: 5.08, 95% CI 1.93-25.7.5, P ¼ 0.001). Because the administered dose of dexamethasone was different in the various regimens (Table 1) and was higher for patients p65 years of age (94% of patients p65 years vs 68% of those 465 years received X160 mg of dexamethasone on first month), we also explored the impact of the dose of dexamethasone on the probability of RI improvement. In univariate analysis, dexamethasone X160 mg during the first month of treatment was associated with increased rates of RI improvement (odds ratio (OR): 3.072, 95% confidence interval (CI) 1.363-6.925, P ¼ 0.007). In order to adjust for differences in the baseline characteristics of the patients and differences in the dose of dexamethasone in the three groups, we performed a multivariate analysis, according to which, bortezomib-based therapy was independently and significantly associated with a 4.25-fold increase (95% CI 1.296-13.941, P ¼ 0.017) in the probability of renalPR or better compared with lenalidomide-based therapy. Thalidomide-based regimens were associated with a non statistically significant 2.36-fold increase (95% CI 0.868-6.405, P ¼ 0.092) in the probability of renalPR or renalCR compared with lenalidomide-based regimens. Compared with thalidomide-based therapy, bortezomib-based therapy was marginally superior (OR: 2.3, 95% CI 0.91-6, P ¼ 0.08), after adjustment for age 465 years, baseline eGFR o30 ml/min and dose of dexamethasone (X160 mg within the first month of therapy). Other factors that were independently associated with a higher probability of major renal response in the multivariate analysis were eGFR X30 ml/min (OR: 2.93, 95% CI 1.278-6.698, P ¼ 0.011), age p65 years (OR: 3.39, 95% CI 1.070-10.752, P ¼ 0.038) and a myeloma response (OR: 2.65, 95% CI 1.081-6.487, P ¼ 0.033) ( Table 3) . However, the dose of dexamethasone X160 mg during the first month was not an independent factor for major renal response (OR: 1.74, 95% CI 0.64-4.5, P ¼ 0.256). When we performed the analysis with the inclusion of the dose of dexamethasone on subsequent cycles of therapy, then again dexamethasone X160 mg per cycle was not an independent predictor of major renal response (P ¼ 0.359).
Because the inclusion of iFLC in the multivariate model decreased the number of patients that could be included in the analysis, we performed an additional analysis for the 102 patients with available iFLC. In this analysis, bortezomib-based therapy was the most important factor associated with major renal response (OR: 6.677, 95% CI 1.5-29.7, P ¼ 0.013). Other factors included again eGFR 430 ml/min (OR: 4.087, 95% CI 1.29-12.924, P ¼ 0.017) and objective myeloma response (HR: 3.945, 95% CI 1.163-13.39, P ¼ 0.028), but not dexamethasone dose X160 mg (P ¼ 0.506), thalidomide-based therapy (P ¼ 0.102), iFLC X500 mg/l (P ¼ 0.295) or age X65 years (P ¼ 0.076).
Prognostic factors for time to renal response Patients in group B achieved at least renalPR in a median of 1.34 months (41 days), whereas for patients in group T median time was 2.7 months (82 days) and for patients in group L exceeds 6 months (P ¼ 0.028) (Figure 2 ). The dose of dexamethasone X160 mg in the first month of therapy was associated with a more rapid major renal response (1.6 vs 46 months for doses o160 mg, P ¼ 0.008). Abbreviations: CR, complete response; eGFR, estimated glomerular filtration rate; RenalCR, renal complete response; renalMR, renal minor response; renalPR, renal partial response.
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An eGFR X30 ml/min was also associated with shorter time to major renal response but this was not statistically significant (1.4 vs 3 months, P ¼ 0.319). For patients with available FLCs, an iFLC X500 mg/l was associated with longer time to major renal response (2.3 vs 1.15 months for iFLC o500 mg/l, P ¼ 0.044). We then examined the timing of myeloma response and renal response. Median time to myeloma response for all patients was 1.5 months (45 days): for those treated with thalidomide was 2 months (61 days), for those treated with bortezomib was 1.12 months (34 days) and for lenalidomide treated patients was 1.25 months (38 days). In 14 patients renal response followed myeloma response by X1 month (median 2.5 months) and in 15 patients renal response preceded myeloma response by at least 1 month (median 3 months), whereas in 44 patients myeloma and renal response occurred o1 month apart (Figure 3) .
When we adjusted for differences between groups in multivariate analysis then bortezomib-based therapy was associated with shorter time to major renal response (OR: 1.71, 95% CI 1.01-3.5, P ¼ 0.048) compared with lenalidomide-based therapy, whereas there was no significant difference between thalidomide and lenalidomide-based therapies (P ¼ 0.141). Dexamethasone at a total dose X160 mg in the first month of therapy was also associated with shorter time to major renal response (OR: 1.82, 95% CI 1-3.33, P ¼ 0.05). An eGFR X30 ml/min (OR: 1.7, 95% CI 1.058-2.73, P ¼ 0.028) and age p65 years (OR: 1.97, 95% CI 1.144-3.4, P ¼ 0.014) were also independently associated with shorter time to major renal response. We then performed the same analysis in the 102 patients with available FLCs: the same factors independently predicted for time to major renal response (that is, bortezomib-based therapies, dose of dexamethasone, age and eGFR) but not iFLCs X500 mg/dl (P ¼ 0.548).
Time to Major Renal Response
RI and survival
The median follow-up for all patients was 17.5 months and the median survival was 44 months. The median survival for patients of groups T, B and L was 36 months, 53 months and 63 months, respectively (P ¼ 0.572). Because RI in patients with myeloma is associated with an increased risk of early death due to various complications, we examined the rates of early deaths: 10 (7.5%) patients died within the first 2 months from initiation of therapy and the corresponding frequencies in groups T, B and L were 10%, 7% and 4%, respectively (P ¼ 0.588). However, early deaths occurred in 12% of patients with an eGFR of o30 ml/min vs 3% of patients with an eGFR of X30 ml/min (P ¼ 0.058).
We then examined the impact of renal recovery on the overall survival of our patients. We performed a landmark analysis at 2 months and we found no significant difference in the survival of patients who achieved renal response vs those who did not achieve a renal response. Even when, we adjusted in a multivariate model for age 465 years, eGFR o30 ml/min/1.73m 2 and myeloma response (XPR), the achievement of renalPR or renalCR was not associated with improved survival.
DISCUSSION
To the best of our knowledge, this is the first analysis that compared the reversibility of RI in newly diagnosed, symptomatic patients with multiple myeloma treated with different novel agent-based therapy. Our analysis included consecutive, unselected patients who were treated in a single center and all received a similar supportive care. Our data show that novel agent-based regimens can improve renal function in the majority of patients with RI. However, bortezomib-and thalidomide-based regimens appeared more efficacious than lenalidomide-based regimens in this setting. Furthermore, bortezomib-based regimens act more rapidly than Immunomodulatory drugs (IMiDs)-based regimens. Our analysis also showed that higher dose of dexamethasone may also decrease time to renal response; however, higher doses of dexamethasone do not seem to improve the probability of renal response in the multivariate analysis. Importantly, for many patients, especially older ones, very high doses of dexamethasone may be poorly tolerated and associated with significant toxicity.
We also found that a major decrease in light chain load is associated with renal response. This is depicted by the fact that in the patients who achieved a renal response we observed 490% reduction of urine light chain excretion and/or of FLCs. This has also been observed in other studies in which FLCs were removed by high cutoff hemodialysis and early reduction of serum FLCs was associated with better renal outcome. 32 Several analyses are supporting the significant role of bortezomib in myeloma patients who present or develop RI. 29, 33, 34 In addition, bortezomib-based therapy plus plasma exchange resulted in a renal response in 86% of patients treated in a single center. 35 In patients with light chain-induced renal failure requiring dialysis, the use of bortezomib plus high cutoff hemodialysis resulted in significant rates of dialysis independence. 36 An ongoing randomized study in patients with cast nephropathy, dialysis-dependent renal failure and new myeloma will compare FLC removal by high cutoff or standard dialysis in patients who receive bortezomib-based chemotherapy (EuLITE-European Trial of Free Light Chain Removal by Extended Hemodialysis in Cast Nephropathy). This activity of bortezomib-based regimens in the setting of myeloma-related RI was also documented in our analysis, which included a large number of unselected patients most of whom had severe renal dysfunction or even were on dialysis, that is, patients who are usually excluded from clinical trials. There are data that indicate that the favorable activity of bortezomib in the context of RI is not only due to its rapid and significant antimyeloma action and its non-renal metabolism, [37] [38] [39] but also due to a 'protective' effect on renal cells and inhibition of inflammatory and fibrotic cascades within kidney microenvironment. Thus, in vitro, bortezomib induced survival signals in a proximal tubular renal cell line. 40 Proteasome inhibition with bortezomib partially blocked light chain-induced monocyte chemoattractant protein-1 (MCP-1) by Src kinase-dependent activation of the NF-kB pathway, and this may be associated with an inhibition of proinflammatory and profibrotic activity within renal microenvironment. 41 The role of thalidomide in myeloma patients with RI has been evaluated less thoroughly. [6] [7] [8] Our group has published data indicating that thalidomide-based regimens are safe and effective in improving renal function in newly diagnosed myeloma. 7 In another recently published study, 8 thalidomide with dexamethasone was given as induction before autologous peripheral blood stem cell transplantation in 31 patients with newly diagnosed multiple myeloma and renal insufficiency (creatinine clearance o50 ml/min), including seven patients who required chronic hemodialysis. An improvement of renal function was observed in 23 patients (in 17 (55%) patients to 450 ml/min), and two of seven patients who were dialysis dependent became dialysis independent. Our data, from the current analysis, indicate that thalidomide-based regimens remain a major treatment option for patients with newly diagnosed myeloma presenting with renal failure can be administered with safety to patients with RI, and a high rate of renal function improvement can be expected.
Lenalidomide is renaly excreted and an adjustment of its dose in myeloma patients with RI is needed. 11 All of our patients received lenalidomide dosed according to renal function; with this approach, no excessive myelosuppression was seen and this is in accordance with previous studies in the relapsed/refractory setting. 13 Lenalidomide with dexamethasone has also been associated with improvement in renal function in patients with relapsed or refractory myeloma. 12, 13 However, in newly diagnosed patients with myeloma presenting with RI, the probability of renal function improvement was lower than that expected with thalidomide and especially compared with bortezomib. Still, a lenalidomide-based regimen may be indicated in myeloma patients with RI who have a contraindication for bortezomib, such as peripheral neuropathy, impaired liver function and so on.
In accordance with an older observation that renal failure was a direct or major contributing factor in at least one-third of early deaths in newly diagnosed myeloma patients. 4 We observed that early deaths occurred in 8% of our patients and actually this rate was as high as 13% in patients presenting with severe renal dysfunction (that is, eGFR o30 ml/min). Thus, despite the use of novel agents, early mortality in patients presenting with RI remains significant, indicating that rapid and effective intervention is needed.
In conclusions, our analysis, for the first time, retrospectively compares the impact of treatments based on thalidomide, bortezomib or lenalidomide on renal function recovery in an unselected population of newly diagnosed myeloma patients, and indicates that bortezomib-based therapies with high dose dexamethasone (at least during the first 1-2 cycles of therapy) should be considered for the initial management of patients with myeloma-related renal dysfunction because of rapid action and high rates of renal recovery. However, thalidomide and lenalidomide can also be considered for patients who cannot receive bortezomib, with significant probability for an improvement in their renal function.
